What Are Wall Street’s Thoughts On AstraZeneca PLC Shares (AZN)?

The stock of AstraZeneca PLC (NASDAQ:AZN) increased by increased by $0.57 on Friday to finish at $61.79, up 0.93 percent. The last five days have seen an average of 3,441,860 shares of common stock traded. 27 times new highs were reached in the current year, with a gain of $11.80. The average number of shares traded over the last 20 days was 4,822,715, while the average volume over the last 50 days totaled 5,506,692.

AZN stock appreciated 3.88% since last month. On 09/28/21, the company’s shares reached a one-month low of $57.10. The stock touched a high of $61.34 on 10/22/21, after rallying from a low of $46.48 in 52 weeks. The price of AZN stock has risen by 23.60% or $11.80 this year, reaching a new high 27 times. Still, the stock price is up 0.73% from the 52-week high.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Valuation Metrics

AstraZeneca PLC (AZN) has a trailing price-to-earnings (P/E) ratio of 43.12. This level actually compares unfavorably with the industry at large, as the PE for the Drug Manufacturers – General industry stands at about 27.25. Further, its PE also compares unfavorably with the Healthcare sector’s trailing 12 months PE ratio, which comes in at 33.43 right now. The PE ratio of AstraZeneca PLC has varied between 99.67 and 18.94 in the last five years. Beta for the stock is 0.47. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 6.43, the price-to-book (PB) ratio of 10.35, and the price-to-cash flow ratio of 111.39.

AstraZeneca PLC’s dividend is $1.37 per share per year. With a dividend yield of 2.22%, AZN has a payout ratio of 65.40%. On Sep. 13, the company paid $0.45 per share in dividends, a decrease of -52.63% from $0.95 last year. A $0.50 dividend decrease was reported on Friday July 30 2021.

For the three months ended June 29, AstraZeneca PLC’s quick ratio was 1.00, while its current ratio was 1.20, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 1.57, and the total debt to equity ratio is 1.75. As far as profitability goes, gross margin for the trailing twelve months is 76.20% percent. AstraZeneca PLC’s EBITDA margin for the year ended June 29 was 27.47%, whereas its operating margin stood at 19.20% for the same period. Based on annual data, it had gross profit of $21.32 billion and revenue of $26.62 billion.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. AZN’s return on assets (ROA) during the last 12 months has been 5.60%. There was a 12.20% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 26.00%. ROE has averaged -15.50 in the past year for the broader industry.

Earnings Surprise

According to AstraZeneca PLC’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $26.62 billion, while revenues rose by 78.12% to $0.0. It was predicted that AstraZeneca PLC’s quarterly earnings would be $0.45, but it ended up being $0.43, beating the consensus by 4.70%. EBITDA was $1.88 billion for the quarter. At the end of AstraZeneca PLC’s most recent quarter ended June 29, its liabilities totaled 57.95 billion, while its total debt was $29.89 billion.

Technical Picture

Here’s a quick look at AstraZeneca PLC’s (AZN) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 66.13%, suggesting the stock is Neutral, with a 16.72% historical volatility rate.

The stochastic %K and %D were 86.20% and 70.44% respectively, while the average true range (ATR) was 0.92. Based on the 14-day stochastic reading of 90.80%, the RSI (14) reading is 62.29%. On the 9-day MACD Oscillator, the stock is at 0.80, and the 14-day reading is at 0.84.

Analyst Ratings

Analysts have assigned AstraZeneca PLC (AZN) an Buy rating. AZN is a stock that is recommended for selling by 0 brokerage firms, while 3 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 2 rates it overweight and 22 others recommend it as a buy.

What is AZN’s price target for the next 12 months?

The current consensus forecast for the stock is between $59.86 and $103.70, with a median target price of $69.08. In analyzing these forecasts, the average price target given by analysts for AstraZeneca PLC (AZN) is $70.65.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Hot Topics

Related Videos

Related Videos

Related Articles

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

592

100% free. stop anytime no spam